These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18180010)

  • 21. A timely reminder about an evolving clinical entity: nephrogenic systemic fibrosis and gadolinium use in CKD.
    Jamboti J
    Nephrology (Carlton); 2007 Jun; 12(3):316. PubMed ID: 17498132
    [No Abstract]   [Full Text] [Related]  

  • 22. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.
    Chewning RH; Murphy KJ
    J Vasc Interv Radiol; 2007 Mar; 18(3):331-3. PubMed ID: 17377176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nephrogenic systemic fibrosis possibly caused by gadolinium-containing contrast agent].
    van der Meij N; Keur I; van Lienden KP; Scheepstra CG; Bos JD
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2898-903. PubMed ID: 18257437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):153-9. PubMed ID: 18343071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.
    Khurram M; Skov L; Rossen K; Thomsen HS; Marckmann P
    Scand J Urol Nephrol; 2007; 41(6):565-6. PubMed ID: 17934986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.
    Shellock FG; Spinazzi A
    AJR Am J Roentgenol; 2008 Oct; 191(4):1129-39. PubMed ID: 18806155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the potential causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2007 May; 25(5):879-80. PubMed ID: 17457806
    [No Abstract]   [Full Text] [Related]  

  • 32. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium.
    Caccetta T; Chan JJ
    Australas J Dermatol; 2008 Feb; 49(1):48-51. PubMed ID: 18186850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
    J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Feb; 56(7):137-41. PubMed ID: 17318112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrogenic systemic fibrosis and gadolinium: a perfect storm.
    Colletti PM
    AJR Am J Roentgenol; 2008 Oct; 191(4):1150-3. PubMed ID: 18806157
    [No Abstract]   [Full Text] [Related]  

  • 36. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
    Marckmann P
    Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link?
    Perazella MA
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):200-2. PubMed ID: 17699407
    [No Abstract]   [Full Text] [Related]  

  • 38. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
    Kuo PH; Kanal E; Abu-Alfa AK; Cowper SE
    Radiology; 2007 Mar; 242(3):647-9. PubMed ID: 17213364
    [No Abstract]   [Full Text] [Related]  

  • 39. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK; Thomsen HS
    Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.